The use of funds raised by this IPO includes the production and commercialization of azvudine, the core product of the company for treating COVID-19, and the clinical development for treating HIV infection, HFMD and some types of blood tumors. In this prospectus, real life did not disclose the number of shares issued and the amount of funds to be raised.
According to the financial data, in 2020, 202 1 year and the first five months of 2022, the company's income was 68,000 yuan, 1.37 million yuan and 845 1 10,000 yuan respectively, and the losses during the period were 1 .5/kloc-0 respectively.
The funds raised will be used for the commercialization of oral drugs in COVID-19.
According to the prospectus, real creatures were established in Pingdingshan City, 20 12. Is an innovative drug research and development enterprise integrating independent research and development, production and sales, mainly engaged in the research and development of innovative drugs such as antivirus, antitumor, cardiovascular and cerebrovascular diseases and liver diseases.
According to the prospectus, AZF, the company's core product, is an innovative drug with broad-spectrum antiviral activity, which was conditionally approved by the State Pharmaceutical Products Administration in July 2026 and July 2022, respectively with the numbers of 2 1 and coronavirus pneumonia-19. This is the first oral direct antiviral drug-19 developed by China Company and approved by the State Administration of Pharmaceutical Products for the treatment of coronavirus pneumonia. The company said that it was fully prepared to start commercial sales of azvudine.
According to the prospectus, in July 2022, the Company and Fosun Pharma (a subsidiary of Fosun Pharma) reached a strategic cooperation agreement on the common development in China Mainland and some potential areas around the world, as well as the exclusive commercialization of Fosun Pharma's treatment and prevention of HIV infection and Azivudine-19 for coronavirus pneumonia.
In addition, the company has reached strategic agreements with many leading pharmaceutical manufacturers in China (including Peking Union Medical College) to produce and supply active pharmaceutical ingredients (API) and afudin tablets for the company. The company also has its own production capacity, with an annual output of about one billion tablets. The company believes that the combination of its own production capacity and contract production capacity will be able to produce enough azvudine to meet the market demand.
One of the investment funds raised in this listing is the manufacture and commercialization of the company's core product, azivudine for the treatment of coronavirus pneumonia-19, which is mainly used to provide funds for the purchase of pharmaceutical raw materials needed for the commercial production of azivudine and to provide funds for the expansion of production capacity of Pingdingshan production plant.
In addition, part of the raised funds will also be used for the clinical development of alfudine in the treatment of HIV infection, HFMD and several types of blood tumors, as well as the planned clinical trial of oral long-acting compound tablets (azvudine _CL- 197) in the treatment of HIV infection, the clinical development of candidate drugs in preclinical or IND stage, strengthening the research and development platform and expanding the product pipeline.
Three weeks of siege.
It is worth noting that it took only three weeks for Afuddin to announce the results of the Phase III clinical trial in COVID-19, to obtain the approval of the conditional registration application, to announce the formal production, and to submit the listing financing application, which is somewhat incredible.
On July 15, real creatures announced the results of the Phase III clinical trial of alfudine in the treatment of COVID-19. The results showed that on the 7th day after the first administration, the improvement rate of clinical symptoms in afudin group was 40.43%, while that in placebo group was 10.87%. The median time of clinical symptom improvement in afudin group was significantly different from that in placebo group (P value 0.0065438+). According to the real biological disclosure, the customs clearance time in COVID-19 is about 5 days.
On July 25th, the State Administration of Pharmaceutical Products conditionally approved the application for increasing the registration of azivudine tablets for treating pneumonia in COVID-19, and requested the marketing license holder to continue the relevant research work, complete the requirements within a time limit and submit the follow-up research results in time.
Then, on August 2nd, the launching ceremony of the oral new drug Afuddin tablets was held in Henan Ruier Biotechnology Co., Ltd., Pingdingshan City Urban and Rural Integration Demonstration Zone, and it was announced that Afuddin was put into production. Wang Chaoyang, founder of Real Biology, said that the approval of azvudine's listing against COVID-19 was an important milestone in the development of Real Biology.
Two days later, on August 4th, real creatures submitted a listing application to the Stock Exchange.
At present, Ruier Bio has signed strategic cooperation agreements with Xinhua Pharmaceutical, China Resources Shuanghe, Aoxiang Pharmaceutical and other domestic pharmaceutical companies. However, the exclusive commercialization right has been given to Fosun Pharma.
On July 25th, Fosun Pharma announced that it had reached a strategic cooperation with real creatures to promote joint development and exclusive commercialization of Azvudine by Fosun Pharma. The above commercialization includes distribution, import, export, sales and promotion. The cooperation areas include COVID-19, AIDS treatment and prevention, and the proposed cooperation areas are China (excluding Hong Kong, Macao and Taiwan) and global areas (excluding South American countries and regions such as Russia, Ukraine and Brazil).
However, what is slightly odd is that in the face of such great benefits, Fosun Pharma ushered in diving after opening sharply higher that day, but fell more than 3% at the close, leaving a long enema, and then fell nearly 15% in the next five trading days.
The loss in two years and five months was 568 million yuan.
In terms of financial data, the company is in a continuous investment period, with little income and continuous losses.
In 2020, 20021year and the first five months of 2022, the company's other income and income were 68,000 yuan, 65.438+0.37 million yuan and 84.565438+0.00 million yuan respectively, and the losses were 654.38+0.5/kloc-0.97 billion yuan respectively. Among them, R&D expenditure is1060,000, 64 million,1140,000 respectively.
By the end of 2020 and the end of 20021,the company's net liabilities were RMB 265,438.07 million and RMB 390 million respectively. According to the company, it is mainly interest-bearing loans and other borrowings, as well as convertible and redeemable preferred shares under current liabilities caused by the accounting treatment of preferred shares. As of May 3, 2022, the company's net liabilities further increased to 564 million yuan, mainly due to the convertible redeemable preferred stock classified as non-current liabilities of 8.3 yuan/kloc-0 yuan.
The above preferred shares mainly come from two rounds of financing in 2020 and 20021,in which the A round of financing was given by Yifeng Capital alone, and the B round was led by Yifeng Capital, with an amount of US$ 6,543.80 billion.
Although the financing amount and R&D investment are not small, the number of employees in the company seems to be small.
According to the prospectus, as of May 3, 2022, the company's internal R&D team consisted of 4 1 members. According to the survey data, in 20021year, the number of people paying social security in the whole company was 33.
If you want to know more real-time financial news, please follow us.